WHAT DOES ABBV-744 IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER (NSCLC) MEAN?

In Segment C, contributors will get ABBV-744 and oral navitoclax. In Phase D, individuals will receive ABBV-744 and ruxolitinib. Individuals will get treatment until sickness progression or even the members are unable to tolerate the study drugs.- "Our study uncovered the critical role of the KLF16/MYC regulatory axis in modulating tumor growth and